Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Recap: AVEO Pharmaceuticals Q2 Earnings
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) moved lower in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share increased 4.76% year over year to ($0.40), which beat the estimate of ($0.45).
AVEO Pharmaceuticals Q2 EPS $(0.40) Beats $(0.45) Estimate, Sales $6.70M Miss $8.94M Estimate
AVEO Pharmaceuticals (NASDAQ:AVEO) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.45) by 11.11 percent. This is a 4.76 percent increase over losses of $(0.42) per share
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
HC Wainwright & Co. Maintains Buy on AVEO Pharmaceuticals, Lowers Price Target to $19
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains AVEO Pharmaceuticals (NASDAQ:AVEO) with a Buy and lowers the price target from $27 to $19.
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.
AVEO Oncology To Hose Key Opinion Leader Webinar On FOTIVDA For Relapsed Or Refractory Renal Cell Carcinoma On July 16
AVEO Oncology (NASDAQ:AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) webinar focusing on FOTIVDA® (tivozanib),